News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00100726-00_29-00A,00.asp?cat=CNS+Tumors&parent=Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4

Posted on: 06/14/2003

39th ASCO Annual Meeting • Chicago, IL • May 31-June 3, 2003 (Abstract No. 446)

Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90

P. Riva, M. Santimaria, M. Casi, M. Adamo, R. Nada, N. Inzaga, Maurizio Bufalini

Hospital, Cesena, Italy; Center of Molecular Immunology, Habana, Cuba

Aim: To asses the clinical effectiveness of loco-regional radioimmunotherapy.

Material and Methods: Loco-regional Radioimmunotherapy (RIT) was performed by administering directly into the post-operative cavity, through an indwelling catheter (Ommaya), a humanised monoclonal antibody hR3 directed against Epidermal Growth Factor Receptors. The Mab was previously linked to DTPA and then labelled with Y-90. The mean dose of protein was 1.5 mg; the mean dose of Y-90 was MBq 721.5. The treatment was repeated, when possible, 3 or 4 times. 45 cases were submitted to RIT: 33 with glioblastoma (30 with recurrent and 3 with newly diagnosed lesion), 7 with recurrent anaplastic astrocytoma, 2 with recurrent grade II astrocytoma and 3 with recurrent anaplastic oligodendroglioma.

Results: We did not record early or late side effects. The mean survival was prolonged: 30 months in glioblastoma group, 49 months in anaplastic astrocytoma series, 83 months in grade II astrocytoma cases and 89 months in anaplastic oligodendroglioma subset. Moreover we observed, in glioblastoma cases 9 deceased, 10 PD, 8 SD, 1 CR and 5 NED. The ORR was 42.4%. In anaplastic astrocytoma patients we obtained 2 deceased, 2 PD, 2 SD and 2 NED (ORR 57.14%). In grade II astrocytoma we observed 1 PD and 1 NED. Finally in anaplastic oligodendroglioma we achieved 1 deceased and 2 SD.

Discussion and Conclusions: These results look better in comparison of the data acquired in two previous trials carried out by utilising antitenascin murine antibody labelled first with I-131 (ORR 24.2% in 74 glioblastoma patients) and, subsequently with Y-90 (ORR 28.5% in 102 glioblastoma cases). Loco regional radioimmunotheray could be effective mainly if it is applied after surgery in cases with minimal residual disease.

© Copyright 2003 American Society of Clinical Oncology All rights reserved worldwide Source: http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00100726-00_29-00A,00.asp?cat=CNS+Tumors&parent= Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740